We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Novel Drug Protects Against Heart Attack and Stroke

By Biotechdaily staff writers
Posted on 06 Feb 2008
A trans-Atlantic partnership will work towards wrapping up the development of a drug designed to prevent cardiac ischemia and stroke by being both cardio-protective and neuro-protective.

Myocardial ischemia, which can be silent or symptomatic, is an intermediate condition in coronary artery disease during which the heart tissue is slowly or is suddenly starved of oxygen and other nutrients. More...
Eventually, the affected heart tissue will die. When blood flow is completely blocked to the heart, ischemia can lead to a heart attack. Ischemia can also occur in the arteries of the brain, where blockages can lead to a stroke. About 80-85% of all strokes are ischemic. Most blockages in the cerebral arteries are due to a blood clot, often in an artery narrowed by plaque.

The drug under investigation is QGC002, a novel recombinant protein that acts to protect against both myocardial ischemia and stroke. The drug was discovered by investigators at the French Institut National de la Santé et de la Recherche Médicale (INSERM), and their partner, Quantum Genomics Corp. (Jersey City, NJ, USA), will fund and conduct pre-clinical development and drug manufacturing. Investigators at Inserm will perform pharmacologic studies in relevant animal models of the targeted diseases.

"This partnership with Inserm provides QGC with a novel first-in-class drug that complements our pipeline,” said Mr. Lionel Ségard, CEO of Quantum Genomics. "It contributes further to enhance our ambition to provide innovative products to treat diseases with significant unmet medical needs.”

"This partnership with Quantum Genomics Corporation gives us a great opportunity to participate in the development of a novel biotherapy,” said Dr. Brigitte Onteniente, senior investigator at INSERM.


Related Links:
INSERM
Quantum Genomics Corporation

New
Gold Member
Aspiration System
VACUSAFE
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
All-in-One Molecular System
AIO M160
New
LAIR2 Antibody Pair Set
LAIR2 Antibody Pair [Biotin]
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Copyright © 2000-2026 Globetech Media. All rights reserved.